| LH |
Report |
Adjusted EPS |
BEAT |
pred ~$4.83 vs. cons $4.78 |
MEDIUM |
| LH |
Report |
Enterprise revenue |
IN-LINE |
pred ~$3.740B vs. cons $3.714B |
MEDIUM |
| LH |
Report |
Quarterly BLS book-to-bill |
MISS |
pred ~1.10x vs. cons 1.121x |
MEDIUM |
| LH |
Guide |
FY26 enterprise revenue |
UNCHANGED |
guide ~$14.65B-$14.80B vs. cons $14.716B |
MEDIUM |
| LH |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$17.70-$18.35 vs. cons $18.05 |
MEDIUM |
| LH |
Guide |
BLS / ED commentary (FY26) |
UNCHANGED |
reaffirm Central Labs mid-single-digit growth; ED flat with stronger 2H vs. UNVERIFIED consensus |
LOW |
| LH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.5% |
— |
LOW |
| LH |
Return |
5-day cumulative residual |
-5.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — unchanged FY guide implies modestly softer H2 estimates |
LOW |